SB 203580

Grouped product items
Size	Price	Qty
5mg	$90.00
50mg	$690.00

Catalog Number : 1524762

description

SB 203580 is a p38 specific inhibitor that prevents the downstream activation of heat shock protein 27 and MAP kinase-activated protein kinase 2 (MAPKAPK2). It can have anti-proliferative activity on cytokine-activated lymphocytes and is reported to be used to enhance cardiomyocyte differentiation.

Additional Information

Applications:	FA
Synonyms:	SB203580, RWJ 64809, CHEMBL10, CTK8E9223
Formulation:	Crystalline solid
Chemical Name:	4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine
Molecular Formula:	C₂₁H₁₆FN₃OS
Molecular Weight:	377.4
CAS Number	152121-47-6
Purity:	≥98%
Storage Conditions:	Product should be kept at -20°C.
References:	Lali, F. V., Hunt, A. E., Turner, S. J., & Foxwell, B. M. (2000). The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. Journal of Biological Chemistry, 275(10), 7395-7402. Barancik, M., Htun, P., Strohm, C., Kilian, S., & Schaper, W. (2000). Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death.Journal of cardiovascular pharmacology, 35(3), 474-483. Martin, J. L., Avkiran, M., Quinlan, R. A., Cohen, P., & Marber, M. S. (2001). Antiischemic Effects of SB203580 Are Mediated Through the Inhibition of p38α Mitogen-Activated Protein Kinase Evidence From Ectopic Expression of an Inhibition-Resistant Kinase. Circulation research, 89(9), 750-752.